OPK

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2004, for eXegenics Inc. (Note: The input metadata references "OPKO HEALTH, INC.", but the filing text explicitly identifies the registrant as eXegenics Inc.). The company is in the process of winding down its historical drug discovery operations and screening for new downstream business opportunities. Effective May 1, 2004, the company relocated its principal executive offices from Dallas, Texas, to Rochester, New York. The company currently has only one employee, David E. Riggs, who serves as President, CEO, and CFO.

Key Financial Metrics

Material Changes Versus Prior Period

• Revenue: The company reported zero revenue for the three and six months ended June 30, 2004, compared to $13,000 in licensing and research fees for the same period in 2003.
• Operating Expenses: General and administrative expenses decreased significantly to $560,000 for the quarter (down from $1,513,000 in 2003) and $1,329,000 for the six months (down from $2,309,000 in 2003). This 63% quarterly decrease is attributed to the completion of the wind-down of drug discovery operations and reduced legal and consulting fees.
• Research and Development: R&D expenses were $0 for the current period, compared to $32,000 (quarter) and $163,000 (six months) in 2003, reflecting the termination of all remaining research programs.
• Strategic Redirection: No new expenses related to strategic redirection were recorded in 2004. In 2003, the company incurred net charges of $299,000 (quarter) and $447,000 (six months) related to severance and program termination, partially offset by reimbursements from Bristol-Myers Squibb.
• Liquidity: Cash and cash equivalents decreased from $10,132,000 at December 31, 2003, to $9,184,000 at June 30, 2004, primarily due to operating cash burn of $1.14 million.

Guidance, Outlook, Risks, and Unusual Items

• Outlook and Cash Usage: Management forecasts cash usage of approximately $100,000 to $125,000 per month, assuming no new investments or business operations. Future capital needs are uncertain, and there is no guarantee that additional financing will be available on favorable terms.
• NASDAQ Delisting Risk: On July 26, 2004, the company received notice of non-compliance with the minimum $1.00 closing bid price requirement. Delisting from the NASDAQ SmallCap Market was stayed pending a hearing scheduled for September 9, 2004. Delisting could adversely impact trading price and liquidity, potentially moving trading to the OTC Bulletin Board.
• Reverse Stock Split: A proposal for a one-for-two reverse stock split was defeated at a special shareholder meeting on July 8, 2004, due to a lack of quorum.
• Legal Proceedings: The company is involved in the "Weiss Litigation" (a derivative suit against former directors) and a federal lawsuit by a former employee ("Labidi Proceeding"). The company believes it has meritorious defenses in the latter.
• Related Party Transaction: The company entered into a lease agreement with RFG Associates, an entity in which the Chairman of the Board is an equity owner, for $625 per month.

Investor Verification Checklist

• Verify the outcome of the September 9, 2004, NASDAQ Listing Qualifications Panel hearing regarding potential delisting.
• Confirm the company's ability to secure additional financing given the monthly cash burn rate of $100,000–$125,000 and the lack of revenue.
• Monitor the status of the "Weiss Litigation" and the "Labidi Proceeding" for potential liability or settlement costs.
• Assess the progress of the "New Board" in identifying and executing a new business strategy to replace the wind-down drug discovery operations.
• Review the company's compliance with NASDAQ listing standards if the delisting is stayed or reversed.